chrisvoncsefalvay/vaers-outcomes huggingface dataset:
tested positive for COVID-19/he was having cold-like symptoms/developed nasty cold; tested positive for COVID-19/he was having cold-like symptoms/developed nasty cold; This is a spontaneous report from a contactable consumer (patient). This 66-year-old male patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 23Jan2021 (Batch/Lot number was not reported) as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. He was scheduled to receive the second dose on 18Feb2021. He tested positive for COVID-19 on 12Feb2021. He was having cold-like symptoms/developed nasty cold. On an unspecified date, reported as "on Sunday", he received bamlanivimab infusion an antibody infusion at the hospital. Outcome of the events was unknown.  Information on the lot/batch number has been requested.
On January 5,2021, developed chills, muscle ache, headache, joint pain ,fever and left arm pain. Taken Acetaminophen
Patient developed acute malaise/fatigue and presented to ED with AKI and + troponins felt to represent acute myocarditis based on cardiology evaluation.  As a hospitalist I will not have ongoing contact with this patient so please contact his PCP,  if additional information is needed.
This spontaneous report was received from a nurse and refers to an unspecified number of patients of unknown age and gender. No information about the patient's medical history, concomitant medications and drug reactions or allergies was reported. On an unknown dates, the patients were vaccinated with improperly stored doses of ROTATEQ oral liquid, lot # M025572 with expiry date 20-JAN-2018, lot # M046008 with expiry date 29-JUN-2018 and lot # M033337 with expiry date 14-APR-2018 (dose was not specified) for prophylaxis. Administered doses of ROTATEQ underwent temperature excursion between 32 Fahrenheit degrees and 35 Fahrenheit degrees for 10 days. Data Logger was involved. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1709USA007903: US-009507513-1709USA013077: US-009507513-1709USA013075: US-009507513-1709USA013076.
Localized redness, warmth, swelling 4 days duration. treated with Benadryl. Onset of symptoms next AM swelling from shoulder to elbow. Child also C/O chest pain without SOB.
Patient felt flush and hot.  Diphenhydramine IM administered in the Emergency Room.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Pharmacist). The reporter is the patient.  An 82-year-old male patient received BNT162b2 (BNT162B2), on 17Feb2021 as dose 1, single (Batch/Lot number: unknown), on 10Mar2021 as dose 2, single (Batch/Lot number: unknown) and on 22Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 81 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical Course: Patient received Paxlovid from 25Jul2022 to 29Jul2022 as COVID 19 Treatment. Patient received other medications within 2 weeks of vaccination.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the information provided, known drug safety profile and plausible temporal association, the causality between BNT162B2 and vaccination failure, Covid 19 cannot be completely excluded.
Information has been received from a physician concerning a patient (a friend at school of his nephew) who on unspecified date was vaccinated with a dose of VARIVAX (Oka/Merck) (Lot # unspecified).  And after vaccination the patient developed a case of chicken pox.  It is unknown if the patient sought medical attention.  At the time of reporting (02-DEC-2008) the outcome of the patient was unknown.  This is one of several reports from the same source.  Additional information has been requested.
Stomach problems; Long term chills; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL DISCOMFORT (Stomach problems) and CHILLS (Long term chills) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010M20A and 012L20A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma, Cholesterol, Arthritis and Migraine. Concomitant products included DICLOFENAC SODIUM, MISOPROSTOL (DICLOFENAC/MISOPROSTOL) for Arthritis, EVOLOCUMAB (REPATHA) for Cholesterol, CODEINE PHOSPHATE, PARACETAMOL, SALICYLAMIDE (FIORINAL [CODEINE PHOSPHATE;PARACETAMOL;SALICYLAMIDE]) for Migraine, ALPRAZOLAM, FLUOXETINE HYDROCHLORIDE (PROZAC), MONTELUKAST SODIUM (SINGULAIR), LEVOTHYROXINE SODIUM (SYNTHROID), TRAZODONE, EZETIMIBE (ZETIA), SUMATRIPTAN and ESTRADIOL (ESTRACE VAGINAL) for an unknown indication.   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ABDOMINAL DISCOMFORT (Stomach problems) and CHILLS (Long term chills). At the time of the report, ABDOMINAL DISCOMFORT (Stomach problems) and CHILLS (Long term chills) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood test: other (normal) Blood test came back normal.         Concomitant products includes Pro Air inhaler, Advair generic.  Reaction/event as reported was chronic, recurrent.
Dentist noticed web-like striations on right bucosal mucosa during routine dental exam and referred patient to oral surgeon. Oral surgeon diagnosed lichen planus and recommended patient get biopsy (scheduled 11/29).
Notice a cyst growing in my left thumb pad not present before the 2nd dose of the Pfizer vaccination received on 10.09.2021.  First available appointment able to see physician was Nov. 30, 2021, but I called and got in sooner on Oct. 28th.  No pain to touch at the time, but there is pain now. Typical response in the medical community: "let's watch and wait." No referral for imaging or to a hand doctor.   After the second shot, I experienced rapid heart rate at the pharmacy, which subsided within the 30 minutes I was required to wait. The next few days I experienced neurological symptoms - shakes, not a cold shiver - by Monday, Oct. 11, I was very lethargic and the shakes subsided.  No fever.
vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 49-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046C21A and 011J20A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. No treatment medication was reported.   This case was linked to MOD-2021-395985 (Patient Link).
Initial healthcare professional report received on 11 Dec 2009: This child (age below 4 years) received one dose of FLUVIRIN H1N1 (batch no. 102142P1) on an unspecified date. No adverse event was reported.
About 15 minutes after receiving Tdap vaccine patient c/o rash to chest and feeling "hot." Pt denied SOB or breathing difficulty. Vital signs 116/74, HR 88, RR 18. Pt given 25 mg BENADRYL PO and pt rested. Denied complaints after resting x 20 minutes.
She was diagnosed with infantile spasms which I believe was caused by the DTAP vaccine. My daughter began dropping her head and I noticed a dazed look on her face. I then realized that she was having a seizure, when the jackknife movements began to last 10 minutes or less. She is currently on her 3rd treatment ACTHAR injections.
Rec'd 0.25 quad. Flu shot at clinic on 10-01-13. Seen 10/03/13 for s/s -> injection site with erythema, warmth and induration. Afebrile; + puffiness. Red area 14 cm x 15 1/2 cm. Dx with cellulitis with mild lymphadenitis. S/S began 10-02-13 PM. Tx with DURICEF 250/5 BID (4ml).
As vaccine was administered into the left deltoid muscle and upon retraction of the needle a marble-like ball immediately formed under the skin and within the muscle. The injection site continued to bleed more than normal. The patient stated that it felt no different than any other vaccine but despite using a 1 inch Syringe that was completely injected into the muscle a marble-size ball formed. The patient was immediately given an icepack and bandage. She was monitored for 15 minutes where the ball shrank slightly prior to leaving feeling fine. She was contacted later that night and the lump was said to still be there but smaller than before. The next day 5/17/22 the patient notified the pharmacy that she was fine.
high dose fluzone was given to the patient instead of requested pfizer covid booster shot. patient was called and patient came back into pharmacy and received pfizer covid booster
positive for Covid, had 2 Pfizer vaccines; positive for Covid, had 2 Pfizer vaccines; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "positive for Covid, had 2 Pfizer vaccines". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: positive for Covid. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical information: Patient has had all the vaccines but if was not known if patient had the booster shot. He also developed a headache and was coughing and took Nyquil PM. The reporter was asking about interactions Paxlovid may have with Dextromethorphan and Guaifenesin. Patient has taken the Paxlovid as treatment for 2 days started it Sunday.  Follow-up attempts are completed. No further information is expected.
pt recv vax between 3FEB97 & 7FEB97; & FEB97 pt devel a chickenpox rash on face & trunk;pt returned to school on 10FEB97;
After receiving Moderna shot in left arm experienced periodically in left arm.  After receiving pills from doctor pain is still there.  At the moment I am being treated for Bell's Palsy.
Patient lost consciousness during the 15 minute waiting period after receiving the vaccine. He was pale and sweating, and lacerated his nose as he fell to the to floor. It appears that he fainted.
Initial report was received 27 December 2008 from an investigator as part of a study for which sanofi pasteur is not a sponsor. A 32 year old female patient with no history of tobacco or drug use. BMI- 23.7, 2 ETOH drinks per week prior to pregnancy, no ETOH after conception received an intramuscular initial dose of ADACEL (lot number C2456A) in the left deltoid. The patient had the following diagnostics performed: 03 November 2005 and 02 May 2006: B+, antibody negative, HBsAg - Negative, HIV-negative, Rubella Immune, Syphilis IgG-negative, Gc/Chlamydia-negative. 03 April 2006, 08 May 2006: normal-ultrasound, single IUP. 08 May 2006: normal genetic screening, first trimester screen was negative. 13 June 2006. 28 June 2008: normal ultrasound, normal anatomy. 30 May 2006: alpha feto protein: normal. The patient's last menstrual period was 08 February 2006. Her estimated date of delivery was 15 November 2006. The patient received PITOCIN for augmentation of labor. The patient had intermediate moderate variables and intermediate late decelerations and mild fetal tachycardia. The patient was diagnosed with chorioamnionitis with a fever > 38.0 in second stage labor with prolonged second stage. She received ampicillin and gentamycin during labor. She had a deep sulcus tear and a second degree laceration. She had a post partum hemorrhage and was given misoprostol and Methergine. She was moved to the operating room and underwent dilation and curettage (D and C), evaluation of a vaginal hematoma, and a repair of sulcal tear under general anesthesia. She received a blood transfusion of two units of packed red blood cells. She delivered a baby boy vaginally on 22 November 2006 at 41 weeks gestation. The baby did not have any congenital anomalies. APGAR score was 8 at one minute and 9 at five minutes. List of Documents held by Sender: None. The reporter for this case is the same as cases 2008-04101, 2008-04102, 2008-04104, 2008-04105, 2008-04106, 2008-04107, 2008-04108, 2008-04109, 2008-04110, 2008-04111, 2008-04112, 2008-04113, 2008-04114, and 2008-04115.
Angina Hx. of HTN, DM, pacemaker presented with CP that radiated to bilateral jaw/chin. VSS. Narrative: After covid19 vaccination, c/o CP with radiation to jaw/chin. denied SOB, nausea or diaphoresis. Monitored for 30 minutes with CP resolved but jaw/chin sensation remained. Brought to ED at 15:25 in stable condition. . In ED, stable vitals, a-paced rhythm w/o ST changes per ED note. Offered OBS admission for further cardiac workup but patient declined and was discharged in stable condition with no CP or jaw/chin sensations present.
Hospitalization: 1/21/2023 - 2/14/2023 (24 day) Presentation to the ED:  COVID + date: 1/21/23 Treatment: Decadron & remdesivir Discharge to:   001A21A 3/6/2021 047A21A 4/3/2021
HEADACHE FEVER BODY ACHES NOT ABLE TO USE ARM, RAPID HEARTBEAT, DIARRHEA
5SEP95 pt called clinic c/o sore lt arm for almost 2months since vax, states muscle is flaccid, tingling sensation when sleeps on arm, swollen & constant pain;MD visit 6SEP95; MD reports no swelling, no inflammation, full ROM, nl neuro exam
Pain and weakness left arm from elbow entire arm to shoulder, no redness in the area of inj. treatment-heat, ADVIL and rest.
Approximately 5 to 10 minutes after receiving injections, child began to have swelling of her lips, ears, upper eyelids, palms and soles as well as pruritis.  She never developed respiratory symptoms.   She received 0.25 mg of Epinephrine IM and 18.75 mg of Benadryl orally. Blood pressure, and respiratory rate remained stable over the next hour and swelling and pruritis diminished in all areas except eyelids.
Reaction during 15 min wait had blotching, redness and hives start. Treated with: Solumedrol 125 mg IM at 13:40 pm  and  AT 13:43 Pm Benadryl 50 mg IM per order of   FNP All symptoms resolved after medication and patient discharge to home 14:50 with Husband no further complaints (BP 129/77-88-20 and Pulse ox 99%
sweating; a little bruising at the injection site; feel foggy; heavy breathing; sore on the vaccination site; Tired; chills; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (sweating), INJECTION SITE BRUISING (a little bruising at the injection site), FEELING ABNORMAL (feel foggy), DYSPNOEA (heavy breathing) and INJECTION SITE PAIN (sore on the vaccination site) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013O20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Artificial sweetener intolerance (Allergic to artificial sugar.(Sucrose)).    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jan-2021, the patient experienced HYPERHIDROSIS (sweating), INJECTION SITE BRUISING (a little bruising at the injection site), FEELING ABNORMAL (feel foggy), DYSPNOEA (heavy breathing), INJECTION SITE PAIN (sore on the vaccination site), FATIGUE (Tired) and CHILLS (chills). At the time of the report, HYPERHIDROSIS (sweating), INJECTION SITE BRUISING (a little bruising at the injection site), FEELING ABNORMAL (feel foggy), DYSPNOEA (heavy breathing), INJECTION SITE PAIN (sore on the vaccination site), FATIGUE (Tired) and CHILLS (chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported. No treatment information provided.
Swelling, redness and tenderness to (L) Deltoid area about 2x3 cm wide in diameter.
After about 10 to 20 minutes of receiving my booster, I experienced what looked like mosquito bites on my left wrist. This rash/reaction progressed, and since I received my vaccine, every day I break out in these red, hot, itchy flares. I believe it is chronic urticaria. I went to urgent care about a week later and was prescribed some steroids. Those worked and I stopped experiencing the flare-ups, but now I am off the meds and still experience bad flare-ups at least once or twice a day.
Severe soreness and inflammation of left arm and shoulder.  Proceeded from not being able to lie down on that side to not being able to lift over the head and difficulty brushing hair or dressing.
Reports approximately twenty minutes after vaccination right arm below injection site to fingers, numbness, tingling noted. Approx. at noon injection site "itchy". Approx at 3:26 PM right pinky finger numb.
When I had the vaccine it's like having COVID-19 all over again, the pigmentation of my hand and all over my body was changing color, my hand was itching. I called the doctor and send me to a Dermatologist, the person I saw took picture of my hand and sent them to different places, another Dermatologist told me to no scratch it. I had COVID-19 in March 2021 before all the shots.
arthritic pain in joints, vertigo, skin rash, visual disturbances, muscle weakness, h/a, soreness-swelling & soreness @ inject site for 7 1/2 mos;
Fever and fatigue started 24 hours after shot, resolved after 48 hours.  Rash, itching, hot. swollen and hardness in skin on upper arm near injection site started after 48 hours, has not yet resolved.
Redness a few inches below the injection site and there was hardness; Redness a few inches below the injection site and there was itching; Redness a few inches below the injection site; Tenderness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INDURATION (Redness a few inches below the injection site and there was hardness), VACCINATION SITE PRURITUS (Redness a few inches below the injection site and there was itching), VACCINATION SITE ERYTHEMA (Redness a few inches below the injection site) and VACCINATION SITE PAIN (Tenderness at injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY) and VITAMINS NOS for an unknown indication.    On 19-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In January 2021, the patient experienced VACCINATION SITE PAIN (Tenderness at injection site). On 25-Jan-2021, the patient experienced VACCINATION SITE INDURATION (Redness a few inches below the injection site and there was hardness), VACCINATION SITE PRURITUS (Redness a few inches below the injection site and there was itching) and VACCINATION SITE ERYTHEMA (Redness a few inches below the injection site). The patient was treated with ARNICA MONTANA, CALENDULA OFFICINALIS (ARNICA COMP) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE INDURATION (Redness a few inches below the injection site and there was hardness), VACCINATION SITE PRURITUS (Redness a few inches below the injection site and there was itching) and VACCINATION SITE PAIN (Tenderness at injection site) had resolved and VACCINATION SITE ERYTHEMA (Redness a few inches below the injection site) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient applied Arnica Gel on the site. Patient did not give consent for Safety to contact them.
Hives all over the body; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Hives all over the body) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, the patient experienced URTICARIA (Hives all over the body). The patient was treated with CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) at a dose of UNK, bid. At the time of the report, URTICARIA (Hives all over the body) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
Pt case to Public Health requesting a Moderna vaccine. She expressed this was her first. She completed her paper work and had received the VIS, the vaccine was administered. Her husband also completed paperwork but before he was vaccinated showed us a vaccine card showing he had received 2 doses of Moderna, the last on 2/21. When pt was asked if she had ever received the  covid vaccine she said a year ago. She said she was called last week by a man who told her she needed to be vaccinated. She did not know who this person was or where he was calling from. We then looked her up on the computer to find she had completed 2 doses of Moderna, the last in feb. 2021.  She was then told that she just received a third dose, based on the information she had given us when she came in today. She was monitored for 15 minutes.
In the middle of May, I woke up one night having foot pain. When I woke up in the morning to stand up the pain was gone. I talked with a few co-workers and they were experiencing the same thing. On 06/06/2021, I woke up with a stinging sensation in my left foot around my toes. From that day on, there has been numbness in my foot, up to my ankle. The feeling would not go away. I started to have numbness in my left hand. The feeling would come and go. It felt almost like a stinging pain. I notice the pain generally occurred between 03:00AM ET - 05:00AM ET. Within a week, the pain moved to my right foot also. I made an appointment with my doctor to have some testing done. I am still having these feelings as of today. The numbness has moved to my knee from my foot and my elbow/shoulder from my hand. Most of this is occurring on the left side of my body. I'm still having testing done and the doctors are not able to figure out what is going on. Tomorrow I am having an MRI because they feel that it may be something with the connection from my brain.
Right shoulder pain and tenderness followed by widespread pruritic rash a few days after vaccination. Patient also feels that developing seizures 9 months later may also be due to vaccine; as well as fatigue that is present now.
Mild rash about an inch wide and 4 inches long in the area of the injection site. Little to no itching. Lasted about 18 hours.
Nausea, vomiting, diarrhea, abdominal pain, dizziness, headaches, anxiety, dehydration, high blood pressure. 6-2-16 - 6-23-16. Prescribed ondansetron and promethazine as well as saline IV, blood work, X-Rays, CAT scan.